



# PromptDegrader™ Platform

First in Class platform to target Intrinsically Disordered Regions of proteins to balance protein homeostasis in oncology, neurology, innate and adaptive immune response, virology, and aging

5 June 2023

RDP

June 5, 2023

Business confidential

1



# Introducing RDP Pharma AG

Team and Facilities



# PromptDegrader™ - R&D Team Leaders



Christian Kuehne – Chief Scientific Officer

20+ years of scientific innovation across multiple modalities and a first mover in the field of targeting intrinsically disordered regions for drugging difficult targets. Dr Kuehne leads the PromptDegrader™ internal team and external collaborations.

Viral Oncology  
Unit

Biologics  
Unit

Chemistry  
Unit



Dr Katharina Strasser



Dr Florian Kellner



Dr Antony Crisp



Laboratory in Tulln, Austria






# PromptDegrader™

**P**roteosomal **O**ral **M**onovalent **P**rotein **T**argeting



# First in Class IDR Targeted Protein Degradator

- Unique platform delivering small molecule candidates:
  - ⊕ FTO, NO PROTAC, NO Molecular glue
  - ⊕ PROMPT suitable to drug > 1.000 IDR- human protein targets
  - ⊕ POC *in-vivo* for HPV / E7
  - ⊕ Early *in-vitro* data for c-MYC
  - ⊕ Triage for multiple targets ongoing; 20 oncology targets shortlisted
  - ⊕ Experienced entrepreneur- & drug development team driving the PromptDegrader™




## PromptDegrader™

The PromptDegrader™ has a monovalent **Mechanism of Action (MoA)** that binds to an **Intrinsically Disordered Region (IDR)** of the **Target of Interest (ToI)** and induces its degradation.

Prompt Degrader™ has no Hook Effect; therefore, it has an improved PK / PD compared to PROTACs.


# PromptDegrader™: IDR Targeting Next Generation of TPD



- ✓ IDRs are considered not druggable\*, but PROMPT can do it
- ✓ NOT only reliant on E3 modulation, like most “molecular glues”.
- ✓ Vastly greater chemical space is available.

# Development Phases

RDP has complete freedom to operate in a TPD market due to our unique IP



# CONTACT



**Dr. Michael Ahrweiler**  
CTO - Business Development

[michael.ahrweiler@rdp-pharma.com](mailto:michael.ahrweiler@rdp-pharma.com)

Amriswilerstrasse 51  
CH-8590 Romanshorn  
Switzerland

Tel. +41 71 466 33 68

[info@rdp-pharma.com](mailto:info@rdp-pharma.com)

[www.rdp-pharma.com](http://www.rdp-pharma.com)